Date updated:07-24-2008
"I don't even know where to begin about the positives of the Genetech (DNA)- Roche deal. First, it confirms the general trend: the dollar is so weak that it is worth buying anything that's name-brand if you are from Europe, including Anheuser-Busch (BUD ), a total creature of the weak dollar. It confirms a second trend that the biotechs are the best buys when it comes to a bank-led slowdown. Finally, there is the sentiment issue. Every time the press has hit something during this abominable era, it has struck pay dirt. The negativity surrounding DNA was so great that even when it reported better-than-expected earnings, the stock took a hit initially until people realized that Avastin really was growing again." - Jim Cramer

-
DNA
N/a - $80.43
- 0.00
- $80.43
Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (DNA) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawned a thousand articles -- that life-saving drugs cost too much -- gave the Swiss giant a chance to bolster its own anemic pipeline by buying what may be the greatest wonder drug of all time in its $43 billion bid, no doubt the beginning price for what will ultimately be a deal close to $100 a share. (I pushed DNA hard here and on "Mad Money" because I have been a huge believer in Avastin and I'm confident that people will pay anything -- or family members will pay anything -- for the hope of three or four months or more of life, or the chance of beating cancer altogether.)

-
AMGN
Amgen Inc. - $56.50
- -1.02%
- $55.98
Just like in 1990, the biotechs -- then led by Amgen (AMGN) -- produced spectacular results as their earnings shined in the face a collapse in the financials.

-
GILD
Gilead Sciences - $46.56
- -0.89%
- $46.00
I bought Gilead (GILD) on Friday for Action Alerts PLUS with the trashing it endured because it spent too much -- consider it the Research In Motion (RIMM) of the group.

-
DVA
Davita Inc - $59.33
- -1.07%
- $59.21
Amgen, coincidentally, has been rallying on a better reimbursement environment from the new Medicare bill, an adjunct to DaVita's (DVA) boost.

-
BIIB
Biogen Idec Inc - $46.92
- -1.12%
- $46.20
Don't forget that the whole group is running, including Biogen (BIIB), as the B section of the Journal shows, and Cephalon (CEPH), which seems like nothing but net lately.

-
CEPH
Cephalon - $55.23
- -1.20%
- $55.09
Don't forget that the whole group is running, including Biogen (BIIB), as the B section of the Journal shows, and Cephalon (CEPH), which seems like nothing but net lately.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Top 5 Small-Cap Stocks: N...
- » Echo5Joker's Portfolio
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 27, 2009 According to Jim Cramer, investors need to know the four enemies of all bull markets. On Wednesday’s “Mad Money” TV show...
By Roberto Pedone Posted on Nov. 27, 2009 According to CNBC’s “Fast Money” traders, the adjustment in the third-quarter GDP figure released on Tuesday from an exp...
By Jonas Elmerraji Posted on Nov. 25, 2009 With Thanksgiving fast approaching, retailers have one thing on their collective minds: Black Friday. After all, the day, whi...
By Jonas Elmerraji Posted on Nov. 24, 2009 Don’t dismiss dividends right now. While stocks may have made significant strides in the rally that’s taken hold of the m...
A. i was a fundie trader until last summer
when that stopped working. been learning
ta since. rate of return depends on when
you want to start counting. sure isn't
anywhere near 72%/yr. i'm a individual
investor. i use etf's probably in 15% of
my trades, most of the time for 1 to 10
days. if you don't know ta yet, i urge
you to take the time to learn it.
there's a lot of it to learn, but it
works. mike
A. The only one I own : SLX,
too hard pick a winner out all of them
Here are some of the largest % gainers from Nov. 27, 2009. more
Here are some of the biggest stocks that made the 52-week high list on Nov. 27, 2009. more
These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more











Comments not available